A Meta-Analysis of 556 Individual COVID-19-Associated Mucormycosis Cases: Learning from the Pandemic

Metagenomic Next-Generation Sequencing of Plasma for Diagnosis of COVID-19-Associated Pulmonary Aspergillosis

“…Indeed, coinfections with Aspergillus and Mucorales may occur relatively frequently. Recently coinfections have been reported in 13% of patients with probable IPA ( 16 ) and also in 7% (26 of 378) of patients with COVID-19-associated mucormycosis ( 26 ). For the latter, coinfection with initial diagnosis of CAPA, potentially triggering inappropriate treatment for mucormycosis, was a major independent risk factor for mortality ( 26 ).…”

“…Recently coinfections have been reported in 13% of patients with probable IPA ( 16 ) and also in 7% (26 of 378) of patients with COVID-19-associated mucormycosis ( 26 ). For the latter, coinfection with initial diagnosis of CAPA, potentially triggering inappropriate treatment for mucormycosis, was a major independent risk factor for mortality ( 26 ). In addition, mcfDNA sequencing also detected P. jirovecii in a patient with PJP pneumonia and C. albicans in a patient with suspected Candida infection (also high MPM value), outlining the broad potential of this test for detecting fungal infections and highlighting the benefits over current species/genus-specific assays.…”